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Background: The effect that sponsorship has on publication rates or overall effect estimates in animal studies is
unclear, though methodological biases are prevalent in animal studies of statins and there may be differences in
efficacy estimates between industry and non-industry sponsored studies. In the present analysis, we evaluated the
impact of funding source on publication bias in animal studies estimating the effect of statins on atherosclerosis
and bone outcomes.
Methods: We conducted two independent systematic reviews and meta-analyses identifying animal studies
evaluating the effect of statins on reducing the risk of atherosclerosis outcomes (n = 49) and increasing the
likelihood of beneficial bone outcomes (n = 45). After stratifying the included studies within each systematic
review by funding source, three separate analyses were employed to assess publication bias in these meta-
analyses—funnel plots, Egger’s Linear Regression, and the Trim and Fill methods.
Results: We found potential evidence of publication bias, primarily in non-industry sponsored studies. In all
3 assessments of publication bias, we found evidence of publication bias in non-industry sponsored studies,
while in industry-sponsored studies publication bias was not evident in funnel plots and Egger’s regression
tests. We also found that inadequate reporting of sponsorship in animal studies is still exceedingly common.
Conclusions: In meta-analyses assessing the effects of statins on atherosclerosis and bone outcomes in animal
studies, we found evidence of publication bias, though small numbers of industry-sponsored studies limit the
interpretation of the trim-and-fill results. This publication bias is more prominent in non-industry sponsored
studies. Industry and non-industry funded researchers may have different incentives for publication. Industry
may have a financial interest to publish all preclinical animal studies to maximize the success of subsequent
trials in humans, whereas non-industry funded academics may prefer to publish high impact statistically significant
results only. Differences in previously published effect estimates between industry- and non-industry sponsored
animal studies may be partially explained by publication bias.
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Valid animal research data can generate and test import-
ant clinical hypotheses, minimizing the potential risk to
patients in clinical trials. In fact, studies of human
disease are often developed and improved upon as the
result of animal research.
However, prior research suggests that there may be a
weak correlation between results in animals studies and
subsequent human trials [1-4]. The differences between
the results from animal research and human studies may
be partially explained by reporting bias in animal studies
[5]. Indeed, the publication or lack of publication of
empirical findings in research studies that depends on
the results’ direction or content is a type of reporting
bias referred to as publication bias.
Publication bias in human clinical trials has been mea-
sured by comparing publications to meeting abstracts,
information on trials approved by human subjects ethics
review committees, trial registries, and trials submitted
to drug regulatory authorities [6-12]. Publication bias is
also estimated using a variety of qualitative and quan-
titative methods, including funnel plots, Egger regres-
sion tests for funnel plot asymmetry, and trim-and-fill
methods [13].
To obviate the risk of publication bias in human trials,
there are now registries of studies, such as Clinicaltrials.
gov which can help reviewers identify all relevant trials.
Many journals require that trials be registered before
publication. Unlike human studies, however, animal
studies do not have a pre-specified registration, though
there have been attempts to develop databanks of animal
studies to help determine the efficacy of selected inter-
ventions. For example, since 2004 animal studies evalu-
ating the efficacy of interventions for stroke have been
collated by the Collaborative Approach to Meta-Analysis
and Review of Animal Data from Experimental Studies
(CAMARADES) [14]. This database has been used in a
number of methodological evaluations of animal studies.
Measuring publication bias in animal studies is chal-
lenging because not only do few registries of animal
studies exist [14] but details about the methods of ani-
mal studies are difficult to obtain from animal ethics
review committees and regulatory authorities. Publica-
tion bias in animal studies is not always considered;
Korevaar and colleagues found that a quarter of all
meta-analyses of animal studies do not assess publica-
tion bias at all [15]. Further, most animal researchers
believe that publication biases are highly prevalent
and that about only 50% of all animal experiments
are published [16], though for-profit researchers, spe-
cifically, felt that up to 90% of animal studies are not
published [16]. Additionally, Timmer and colleagues
found that most abstracts of experimental studies
(76%) submitted to a conference were never published,suggesting that non-publication of results may lie with
the study’s authors [17].
Though there are methods to estimate publication bias
and to quantify the effect that the absence of unpub-
lished data may have on the overall efficacy of a treat-
ment, rarely have investigators been able to estimate the
effect of publication bias in meta-analyses of animal
research due to the paucity of systematic reviews of ani-
mal studies. However, publication bias has previously
been identified in animal studies of stroke [18] and
neurological disorders [5]. Specifically, based on statis-
tical modeling, Tsilidis and colleagues found that the
number of animal studies of neurological disorders with
statistically significant positive results far exceeds the
expected number of animals studies with positive results
[5]. And Sena and colleagues estimated that about one-
third of the overall efficacy reported in systematic
reviews of stroke in animal studies might be due to pub-
lication bias [18]. Further, the researchers estimated that
an additional 14% of studies were performed and unpub-
lished [18]. The association of industry funding and bias
in human clinical studies has been studied extensively.
Lundh and colleagues found that compared to non-
industry sponsored human studies, industry-sponsored
human studies more often have favorable efficacy results
and conclusions which cannot be completely explained
by differences in methodology [19].
In the present analysis, we examine whether there is
evidence of publication bias in animal studies by expand-
ing the previously performed systematic review and
meta-analysis of statins and their effect on atherosclerosis
outcomes to include an additional systematic review and
meta-analysis of statins and their effect on bone outcomes.
As a possible explanation for the larger efficacy estimates
observed among non-industry sponsored studies com-
pared with industry-sponsored studies, we hypothesize
that publication bias is more evident in non-industry
sponsored studies than industry-sponsored studies across
various outcomes of interest.
Methods
Inclusion/exclusion criteria
We reviewed abstracts of all citations and retrieved stud-
ies based on the following inclusion criteria: (1) study
conducted in animals (2) original research, defined as a
study that presented original data and did not specific-
ally state that it was a review (3) statin drug compared
to either a non-statin drug or placebo (4) efficacy out-
comes measured (5) assessed effect of statin on at least
one clinically relevant atherosclerosis or bone-related out-
come (including atherosclerosis–vessel measures, plaque
measures, incidence of lesions, measurements of occlu-
sion, plaque type/severity, coronary stenosis, and/or
plaque stability; bone—rate formation, bone size, bone
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composition).
Studies with the primary objective of assessing the
effect of a combination of a statin and another drug
were included if a comparison between a statin-only
treatment group and the other drug was made. For
further details about inclusion and exclusion criteria,
see our previous review [20]. The Institutional Review
Board at University of California, San Francisco, ap-
proved these reviews.
Search strategy
We searched Medline from January 1966 to April 2012
using a search term combination developed with input
from expert librarians.
See Additional file 1 and previous work [20] for more
specific details regarding the search strategy and data
collection/extraction (e.g., author characteristics, coding
of primary results, and financial ties of primary study
authors).
Sponsorship source
The source of sponsorship for each study was catego-
rized as (1) any industry; (2) fully non-industry; and
(3) no sponsorship statement.
Statistical analysis-meta analyses
The meta-analytical statistical methods employed for
both reviews have been described in our previous publi-
cation [21]. In brief, for the meta-analysis, we extracted
data for mean outcome, standard deviation (SD) or
standard error (SE), and the number of treated and
untreated animals to test our hypothesis that the effect
sizes of atherosclerosis and bone outcomes are affected
by industry sponsorship and/or increased risks of bias.
We calculated the effect of statins using a standardized
mean difference (SMD) for each outcome and we pooled
the data across studies using random-effects models [22]
for each type of study—studies of statin use on reducing
atherosclerosis harms outcomes, and studies of statin
use on improving beneficial bone outcomes. The SMD
null hypothesis (Ho: estimate = 0) states that there is no
difference in effect of statin-use on risk of atheroscler-
osis harms outcomes or likelihood for beneficial bone
outcomes when compared to a control/placebo. A num-
ber less than zero suggests that the statin reduces the
risk of atherosclerosis harms outcomes or reduces the
likelihood of beneficial bone outcomes when compared
to control or placebo. A number greater than zero sug-
gests that the statin increases the risk of atherosclerosis
harms outcomes or increases the likelihood of beneficial
bone outcomes when compared to the control or
placebo.Statistical analysis-publication bias assessments
Three separate analyses were employed to assess publi-
cation bias—funnel plots, Egger’s Linear Regression,
and the Trim and Fill methods. The effects of statins
on atherosclerosis outcomes and bones outcomes were
examined separately because of the heterogeneity of
the outcomes and the direction of beneficial effect.
We stratified the pooled effect estimates by declared
sponsorship sources to evaluate differences in risks of
publication bias by funding source.
Funnel plots
A qualitative method for analyzing publication bias is
the funnel plot. The x-axis in the present analysis is the
treatment effect (SMD) and the y-axis is the standard
error of that treatment effect. In the absence of bias, a
funnel plot should be a symmetrical inverted funnel. In
the presence of bias, smaller studies with no beneficial
effects would be missing, thus creating an asymmetrical
funnel. Asymmetry in a funnel plot suggests that there is
a systematic difference between larger and smaller stud-
ies and/or that there is publication bias.
Egger’s linear regression
Funnel plot asymmetry can be tested using Egger’s linear
regression method. The standardized treatment effect is
regressed on the precision—with the weight equal to the
precision, a weighted regression of the treatment effect
size on its standard error is calculated. In the absence of
bias, the bias coefficient would be close to zero and the
regression line would have no slope. In the presence of
bias, bias coefficients will be significantly different than
zero and the regression line will have a slope.
Trim and fill
We also used the trim and fill method of assessing the
potential effect missing studies may have had on our
observed results. After estimating the number of studies
in the outlying side of a funnel plot assumed to be
affected by publication bias, the method trims off the
“asymmetric” side and uses the symmetric remaining
studies to estimate the true center of the funnel plot.
Lastly, the trimmed studies are replaced with their miss-
ing “counterparts” around the center. While this method
should not be viewed as an adjustment for publication
bias, it allows for estimating the potential impact of pub-
lication bias on pooled estimates.
Statistical analyses were conducted using R packages
rmeta, meta, and metafor.
We conducted a sensitivity analysis by categorizing
studies with no disclosed sponsorship as industry spon-
sored. We based this recategorization on the assumption
that funding for industry sponsored studies is less likely
to be disclosed than funding from other sources such as
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ment of their funding.Results
Summary effects
Using random-effects models, we conducted two in-
dependent systematic reviews and meta-analyses iden-
tifying animal studies evaluating the effect of statins
on reducing the risk of atherosclerosis outcomes and
increasing the likelihood of beneficial bone outcomes.
In the atherosclerosis studies, efficacy was defined as
a decrease in a measure of atherosclerosis. We identi-
fied 49 unique studies evaluating 184 atherosclerosis
outcomes in 3498 animals and the pooled effect was
SMD = −1.25 (95% CI −1.56, −0.94) with substantial het-
erogeneity (I2 = 73%) (Table 1). A large proportion of
these studies was funded by non-industry sources (n = 23),
while industry sources funded 15 studies and 11 studies
had no funding statement. In the bone studies, efficacy
was defined as an increased in beneficial bone outcomes.
We identified 45 unique studies evaluating 654 beneficial
bone outcomes in 1986 animals and the pooled effect was
SMD= 0.42 (95% CI 0.00-0.83) with substantial hetero-
geneity (I2 = 89%). The majority of studies of bone out-
comes were by non-industry sources (n = 28), and only 6
studies were funded by industry sources, while 11 studies
failed to disclose a funding source.
Industry sponsored studies had smaller efficacy esti-
mates than non-industry sponsored studies (Table 1).
The efficacy of statins on reducing atherosclerosis (e.g.,
summary effect sizes) among industry-sponsored ath-
erosclerosis studies (−0.73; 95% CI −1.00, −0.47) was
significantly less than the efficacy estimates among
non-industry sponsored studies (−1.99; 95% CI −2.68,
−1.31) (test for subgroup differences p value < 0.001).
There was no significant difference in beneficial bone
outcomes between industry sponsored (0.13; 95% CITable 1 Effect size by outcome and funding source











*Standardized Mean Difference As Estimated in DerSimonian Laird Random-Effects−0.48, 0.73) and non-industry sponsored studies (0.48;
95% CI −0.10, 1.06) (p value = 0.41).Publication bias assessments
Funnel plots
Across all studies, (Figure 1; panels a, e) there appears to
be publication bias in both atherosclerosis and bone
studies as assessed by funnel plot asymmetry. After
stratification by funding source, bias appears to remain
in atherosclerosis and bone studies with no industry
sponsorship (Figure 1; panels b, f ), though bias is not as
apparent in studies with industry sponsorship (Figure 1;
panels c, g).Egger’s linear regression
Funnel plot asymmetry was tested using Egger’s linear
regression. Across all studies, (Figure 2; panels a, e)
there appears to be bias in both atherosclerosis and bone
studies. For atherosclerosis studies, the bias coefficient is
−4.17 (95% CI −5.61, −2.73; p value < 0.0001), while for
bone studies the bias coefficient is −2.43 (95% CI −4.42,
−0.43; p value = 0.021). After stratification by funding
source, bias (i.e., funnel plot asymmetry) appears to
remain in atherosclerosis and bone studies with no
industry sponsorship (Figure 2; panels b, f )—bias coeffi-
cients: −4.83 (95% CI −7.25, −2.41; p value < 0.0001),
−2.80 (95% CI −5.42, −0.17; p value = 0.043), respect-
ively. However, bias is absent in industry-sponsored
studies of atherosclerosis and bone outcomes (bias co-
efficients: −1.56; 95% CI −4.26, 1.15; p value = 0.270.
-2.95; 95% CI −6.60, 0.69; p value = 0.180, respectively)
(Figure 2; panels c, g). Similarly, bias is absent in stud-
ies with no statement of sponsorship (−2.91; 95% CI
−5.96, 0.13; p value = 0.088. 3.30; 95% CI −2.11, 8.71;
p value = 0.253, in atherosclerosis and bone studies,
respectively) (Figure 2; panels d, h).imals Heterogeneity (I2) Effect size* (95% CI)
73 −1.25 (−1.56, −0.94)
18 −0.73 (−1.00, −0.47)
84 −1.99 (−2.68, −1.31)
0 −0.93 (−1.24, −0.61)
89 0.42 (0.00, 0.83)
60 0.13 (−0.48, 0.73)
91 0.48 (−0.10, 1.06)
80 0.39 (−0.36, 1.14)
Models.
Figure 1 Funnel plots. Data from meta-analyses of atherosclerosis studies (a-d) and bone studies (e-h). Funnel plots show standard error plotted
against standardized mean difference with diagonal lines showing the expected 95% confidence intervals around the summary estimate. In the
absence of heterogeneity, 95% of studies should lie within the diagonal lines.
Anglemyer et al. BMC Medical Research Methodology  (2015) 15:12 Page 5 of 10Trim and fill
Across all studies, the pooled effect of statins on athero-
sclerosis outcomes is −1.25 (95% CI −1.56, −0.94). After
trimming and imputing 12 studies, the pooled estimate
is smaller (SMD = −0.76; 95% CI −1.13, −0.39), which
suggests that in the absence of publication bias the sum-
mary estimate may have been approximately 40% lower
than the estimate we obtained (Figure 3; panel a). Over-
all, the 12 “missing” studies accounted for an additional
24% more studies than those identified in our systematic
review. This is an estimate for the percentage of con-
ducted animal studies that were unreported or not iden-
tified in our review. After stratification by funding
source, the pooled effect of statins on atherosclerosis
outcomes in studies without industry sponsorship is
−1.99 (95% CI −2.68, −1.31) and the pooled effect after
the trim and fill method (5 studies) is reduced (−1.25;
95% CI −2.05, −0.45) (Figure 3; panel b), a summaryeffect approximately 40% lower than the summary esti-
mate obtained in the meta-analysis. The 5 “missing”
studies accounted for an additional 22% of animal stud-
ies without industry sponsorship that were unreported.
The pooled effect of statins on atherosclerosis outcomes
in studies with industry sponsorship is −0.73 (95% CI
−1.00, −0.47) and the pooled effect after the trim and fill
method (3 studies) is reduced (−0.58; 95% CI −0.89,
−0.28) (Figure 3; panel c), a summary effect approxi-
mately 20% lower than the summary estimate obtained
in the meta-analysis. The 3 “missing” studies accounted
for an additional 20% of animal studies with industry
sponsorship that were unreported. The pooled effect of
statins on atherosclerosis outcomes in studies with no
sponsorship statement is −0.93 (95% CI −1.24, −0.61)
and the trim and fill method identified no “missing”
studies (Figure 3; panel d), suggesting no publication
bias present.
Figure 2 Egger’s linear regression method. Data from meta-analyses of atherosclerosis studies (a-d) and bone studies (e-h). Plots show the
standardized treatment effect plotted against precision (inverse of standard error). In the absence of funnel plot asymmetry, the slope of
the regression line will be zero.
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tins on bone outcomes is 0.42 (95% CI 0.00, 0.83).
After trimming and imputing 1 study, the pooled esti-
mate is slightly increased (SMD = 0.50; 95% CI 0.06,
0.93) (Figure 3; panel e), an estimate approximately
16% greater than the summary estimate obtained in
the meta-analysis. The 1 “missing” study accounted for
an additional 2% of conducted animal studies that
were unreported. After stratification by funding source,
the pooled effect of statins on bone outcomes in stud-
ies without industry sponsorship is 0.48 (95% CI −0.10,
1.06) and the pooled effect after the trim and fill method
(1 study) is increased (0.63; 95% CI 0.02, 1.24), an estimate
approximately 30% greater than the summary estimate
obtained in the meta-analysis (Figure 3; panel f). The 1
“missing” studies accounted for an additional 4% of con-
ducted animal studies that were without industry sponsor-
ship that were unreported. The pooled effect of statins on
bone outcomes in studies with industry sponsorship is
0.13 (95% CI −0.48, 0.73) and the pooled effect after the
trim and fill method (3 studies) is substantially changed(0.69; 95% CI 0.02, 1.37) (Figure 3; panel g). The 3 “miss-
ing” studies accounted for an additional 50% of conducted
animal studies that were sponsored by industry and were
unreported. The pooled effect of statins on bone out-
comes in studies with no statement of industry sponsor-
ship is 0.39 (95% -0.36, 1.14) and the trim and fill method
identified 0 “missing” studies (Figure 3; panel h).
Sensitivity analysis
To estimate the effect of non-disclosure of sponsorship
on our results, we performed all analyses after re-
categorizing each study without a sponsorship statement
as an industry-sponsored study (see Additional files 2, 3,
4 and 5). Differences between industry and non-industry
studies are less pronounced, particularly for estimates
from Egger’s regression tests. Specifically, publication
bias remains absent in bone studies with industry
sponsorship (Additional file 4: Figure S2; panel f )—bias
coefficient: 0.24 (95% CI −3.19, 3.67; p value = 0.891).
However, in atherosclerosis studies with industry spon-
sorship, publication bias is present −2.13 (95% CI
Figure 3 Trim and fill method. Data from meta-analyses of atherosclerosis studies (a-d) and bone studies (e-h). Funnel plots show the standard
error plotted against the standardized mean difference. The imputed missing studies are shown as open circles on the plots.
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panel c), suggesting that assuming that studies without
sponsorship statements are industry-sponsored can have
an important impact on the estimates.
Discussion
In meta-analyses assessing the effects of statins on
atherosclerosis and bone outcomes in animal studies, we
found potential evidence of publication bias. Further,
this publication bias is more prominent in non-industry
sponsored studies. Using 3 different estimates of publi-
cation bias, we found evidence of publication bias in
non-industry sponsored studies, though in industry-
sponsored studies publication bias was only evident in
funnel plots and Egger’s regression tests. These findings
support our hypothesis that publication bias is more
evident in non-industry sponsored studies than industry
sponsored studies. Thus, the greater efficacy estimatesobserved in meta-analyses of non-industry sponsored
animal studies compared to industry sponsored studies
[21] may be due to the failure to publish negative non-
industry sponsored studies.
In this study, the meta-analyses of both atherosclerosis
and bone outcomes show that the effects of statins mea-
sured in non-industry sponsored studies yielded greater
efficacy than industry-sponsored studies, while displaying
signs of publication bias. However, results from athero-
sclerosis and bone outcomes from industry-sponsored
studies, while yielding smaller effects, displayed fewer
signs of publication bias. Though trim-and-fill methods
in industry-sponsored studies of bone outcomes suggest
the possibility of publication bias, there were only 6 iden-
tified industry-sponsored studies, making the trim-and-
fill results difficult to interpret. In sensitivity analyses in
which the studies without a statement of financial support
were re-categorized as industry-sponsored, publication
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outcomes.
Publication bias is one possible reason for observed,
perceived industry bias [19]. The extent that sponsorship
influences overall effect estimates in animal studies is
unclear. We previously found that the effect of statins
on atherosclerosis efficacy outcomes was significantly
larger for animal studies sponsored by non-industry
sources versus studies sponsored by industry [21], but a
meta-analyses of the effects of thiazolidiones on glucose
reduction in animals had conflicting results [23]. Further
investigation of funding bias in larger cohorts of animal
studies is needed. Substantial methodological risks of
bias existed across all studies in our animal sample,
although we could not detect differences in risks of bias
between the non-industry and industry sponsored stud-
ies. Therefore, publication bias is a possible explanation
for the larger effect sizes observed in the non-industry
sponsored animal studies compared to the industry-
sponsored studies.
Though rarely studied, publication bias in animal stud-
ies has been noted in previous analyses [5,18]. Overall,
animal studies with statistically significant results are
much more likely to get published than studies with
neutral or statistically non-significant results [15,16,24].
Sena and colleagues studied publication bias in animal
studies and estimated that due to “missing” or unpub-
lished studies the efficacy reported in 525 publications
was overestimated by approximately 31% [18].
Reasons for differences in the extent of publication
bias in industry and non-industry funded studies are
not clear. Though we found little evidence of publica-
tion bias in industry-sponsored studies, ter Riet and
colleagues surveyed laboratory animal researchers in
for-profit settings and they estimated that only about
10% of their animal research ever gets published, while
non-industry sponsored researchers report that 80% of
their work is published [16]. This study speculated that
potential causes of the low publication rate among for-
profit animal researchers could include opinions of
peer reviewers and no statistically significant findings
[16]. Conversely, industry and non-industry funded
researchers may have different incentives for publica-
tion. Industry may have a financial interest to publish
all preclinical animal studies to maximize the success
of subsequent trials in humans, whereas non-industry
funded academics may prefer to publish high impact
statistically significant results only [25].
Studies of publication bias in human research have
suggested additional factors that may be associated with
a lack of publication. Vulnerability to publication bias in
human studies is more prominent in specific research
areas and authorship regions [26]. In fact, there is
evidence that industry-sponsored and US-based studiesare more likely to be published than non-industry spon-
sored or non-US based studies [27]. Furthermore, high
quality studies and studies where the publishing journal
is located in the same country as the corresponding
author are more likely to be published [10]. It is believed
that any regional difference may be partially explained
by the assumption that researchers in some regions are
often faced with greater expectations to publish, while
results from researchers in other regions are usually only
published if considered overtly impactful [26]. And, edi-
torial boards of English language journals are mainly
comprised of Americans, which could also lead to a bias
in favor of US research [27,28]. Though it has been sug-
gested that US researchers may report more positive and
statistically significant results [29], others have not found
similar results [27].
There have been recent efforts to improve reporting
standards for animal research, and we have shown that
reporting of randomization, accounting for all animals,
and sample size have improved slightly since the publi-
cation of the ARRIVE guidelines [21]. However, guide-
lines for reporting animal research have focused on
reporting risk of bias and other characteristics of the
studies, rather than ensuring that entire studies and full
outcomes are reported [30,31]. While medical journals
have taken steps to improve mandatory reporting and
follow-up of protocols in human studies by requiring
registration of studies before publication [32], the same
requirements have not yet been established for labora-
tory animal research. Prospective registration of animal
studies, release of information on animal studies that
have received ethical approval, and having funders
require publication of the results of animal studies are
other possible ways to reduce publication bias in animal
research [30,31]. Further, through registration and publi-
cation of animal studies, future human volunteers may
have less unnecessary enrollment in trials [33].
This study of publication bias should be interpreted
with an understanding of the inherent limitations. First,
though we performed an exhaustive search and system-
atic review of animal studies and their effects on athero-
sclerosis and bone outcomes, we may have missed some
relevant studies. The trim-and-fill results indicate that
there are “missing” industry and non-industry sponsored
studies, suggesting publication bias. However, these
“missing” studies could also be studies that were not
identified in our search. Second, we may have lacked
reasonable dispersion of the sample size to get a robust
estimate of publication bias. In fact, due to a small sam-
ple size of industry-sponsored studies evaluating bone
outcomes, the results that failed to indicate publication
bias in this subgroup, in particular, may have occurred
as a result of Type II error. However, in the sensitivity
analysis in which we re-categorized studies with no
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sion test for funnel plot asymmetry remained non-
significant (p value = 0.891). Third, the impression of
publication bias as illustrated in the funnel plots may be
an artifact of high precision studies truly having a differ-
ent effect size. However, the funnel plots, if considered
together with Egger’s regression test and the trim-and-
fill methods remain suggestive of publication bias. And
while the Cochrane Handbook recommends a minimum
of 10 studies to be included in any publication bias ana-
lysis [34], we acknowledge that with a larger sample
size of studies identified in each subgroup (particu-
larly industry-sponsored studies of bone outcomes)
we would have likely gained more insight regarding
the presence of publication bias. Fourth, in the sys-
tematic reviews, many of the studies we included had
small samples sizes and measured multiple outcomes
in a single animal. Additionally, the data we evaluated
included disparate outcomes, durations of follow-up,
different species, and different types of statins. All of
these factors could contribute to the overall hetero-
geneity in the results; the impacts these differences
have on publication bias is unknown. Further details
and our methods for dealing with these issues are
previously described [21]. Lastly, our results are only
generalizable to the research questions specifically
reviewed in the two systematic reviews (e.g., bone
outcomes and atherosclerosis). Though publication
bias may be prominent in multiple areas of animal
research, the direction and strength of this bias is
unpredictable based on our present results.
Conclusions
We employed multiple methods used to assess publi-
cation bias and our analyses suggest that there is evi-
dence of publication bias in non-industry sponsored
studies, while in industry-sponsored studies publication
bias is not as evident. Furthermore, we note that inad-
equate reporting of sponsorship in animal studies is
very common. Differences in results between industry-
and non-industry sponsored animal studies may be
partially explained by publication bias.
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